Search
Generic filters
Search in excerpt

Vaccine

Syvazul® BTV 3 suspension for injection

Syvazul BTV 3 injectable suspension for sheep and cattle.

Important information: Syvazul® BTV 3 is currently authorised in European countries (Art. 25) for the active immunisation of sheep to reduce viraemia, mortality, clinical signs and lesions caused by bluetongue virus serotype 3, using a vaccination protocol of one subcutaneous injection of 2 mL from 3 months of age. On 17 July 2025, the CVMP issued a favourable opinion for a variation to include bovine species, with a dose adjusted to 2 mL, obtained by a concentration process and containing the same amount of antigen as the previously used 4 mL dose. This represents a significant advance, improving user comfort and aligning with the latest regulatory data. The proposed indication is the active immunisation of bovine livestock to reduce viraemia caused by bluetongue virus serotype 3, using a protocol of two intramuscular injections of 2 mL administered at an interval of three weeks. More information : https://www.ema.europa.eu/en/medicines/veterinary/variation/syvazul-btv-3

Quick product information

Active ingredient(s)Posology*Waiting timePackaging

Bluetongue virus, serotype 3 (‘BTV-3’), strain BTV-3/NET2023, inactivated ≥ 107.2 CCID50

Sheep: Subcutaneous use.
From 3 months of age – Primary vaccination: administer a single 2 ml dose.

Cattle: Intramuscular use

From two months of age – Primary vaccination: administer two 2 ml doses three weeks apart.

Zero days.

Vials 80 ml and 200 ml

Country Availability

Netherlands, Belgium, Germany, United Kingdom, Austria, Spain, Portugal, Sweden, Denmark, Italy, Switzerland, France, Poland, Bulgaria, Czech Republic, Croatia, Cyprus, Estonia, Finland, Greece, Hungary, Ireland, Latvia, Lithuania, Luxembourg, Malta, Romania, Slovakia, Slovenia.

If your country is not listed, please contact our export team.

Contactar

Active ingredient(s)

Bluetongue virus, serotype 3 (BTV-3), strain BTV-3/NET2023, inactivated ≥ 107.2 CCID50*.
*CCID50: 50% infectious dose in cell culture, determined prior to inactivation
Adjuvants:
Aluminium hydroxide (Al3+) 2.08 mg
Purified saponin (Quil-A) from Quillaja saponaria 0.2 mg
Excipient:
Thiomersal 0.1 mg

Indications

Sheep:
For active immunisation of sheep to reduce viraemia, mortality, clinical signs and
lesions caused by bluetongue virus serotype 3.
Establishment of immunity: 4 weeks after completing the primary vaccination schedule.
The duration of immunity has not been established.

Cattle:
For the active immunisation of cattle to reduce viraemia caused by serotype 3 of the Bluetongue
virus.
Establishment of immunity: 3 weeks after completing the primary vaccination schedule.
The duration of immunity has not been established.

Special precautions

  • Only vaccinate healthy animals.
    No information is available on the use of the vaccine in sheep and cattle with maternal antibodies.

Posology

Sheep: Subcutaneous route.
Administer subcutaneously to sheep from 3 months of age, according to the following
schedule:
– Primary vaccination: administer a single 2 ml dose.

Cattle: Intramuscular administration.
Administer intramuscularly to cattle from 2 months of age in animals without
previous treatment or from 3 months of age in calves born from immunised mothers,
according to the following schedule:
– Primary vaccination: administer two 2 ml doses separated by an interval of 3 weeks.

Revaccination: Not established.

Waiting time

Zero days.

Packaging

Vials of 80 ml and 200 ml

With veterinary prescription